NCT04858269View on ClinicalTrials.gov

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

August 31, 2027

Conditions
Head Neck CancerMetastatic Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaOropharynx Squamous Cell CarcinomaHypopharynx Squamous Cell CarcinomaLarynx Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle

DRUG

Carboplatin

Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle

DRUG

Paclitaxel

Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.

Trial Locations (1)

27157

Wake Forest Baptist Health Sciences, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER